EP1224296A1 - L-pantolactone-hydrolase and a method for producing d-pantolactone - Google Patents
L-pantolactone-hydrolase and a method for producing d-pantolactoneInfo
- Publication number
- EP1224296A1 EP1224296A1 EP00972817A EP00972817A EP1224296A1 EP 1224296 A1 EP1224296 A1 EP 1224296A1 EP 00972817 A EP00972817 A EP 00972817A EP 00972817 A EP00972817 A EP 00972817A EP 1224296 A1 EP1224296 A1 EP 1224296A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pantolactone
- nucleic acid
- acid sequence
- microorganism
- hydrolase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- SERHXTVXHNVDKA-BYPYZUCNSA-N (R)-pantolactone Chemical compound CC1(C)COC(=O)[C@@H]1O SERHXTVXHNVDKA-BYPYZUCNSA-N 0.000 title claims abstract description 38
- 238000004519 manufacturing process Methods 0.000 title abstract description 12
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 59
- SERHXTVXHNVDKA-SCSAIBSYSA-N (3s)-3-hydroxy-4,4-dimethyloxolan-2-one Chemical compound CC1(C)COC(=O)[C@H]1O SERHXTVXHNVDKA-SCSAIBSYSA-N 0.000 claims abstract description 41
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 34
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 34
- 244000005700 microbiome Species 0.000 claims abstract description 20
- 239000013598 vector Substances 0.000 claims abstract description 15
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 10
- 108090000604 Hydrolases Proteins 0.000 claims description 54
- 102000004157 Hydrolases Human genes 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 49
- 238000006243 chemical reaction Methods 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 33
- 230000008569 process Effects 0.000 claims description 30
- 229940115458 pantolactone Drugs 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
- SERHXTVXHNVDKA-UHFFFAOYSA-N pantolactone Chemical compound CC1(C)COC(=O)C1O SERHXTVXHNVDKA-UHFFFAOYSA-N 0.000 claims description 18
- SIEVQTNTRMBCHO-UHFFFAOYSA-N pantolactone Natural products CC1(C)OC(=O)CC1O SIEVQTNTRMBCHO-UHFFFAOYSA-N 0.000 claims description 18
- OTOIIPJYVQJATP-SCSAIBSYSA-N (2s)-2,4-dihydroxy-3,3-dimethylbutanoic acid Chemical compound OCC(C)(C)[C@H](O)C(O)=O OTOIIPJYVQJATP-SCSAIBSYSA-N 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 8
- 230000033228 biological regulation Effects 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 4
- 241000589158 Agrobacterium Species 0.000 claims description 3
- 241001135755 Betaproteobacteria Species 0.000 claims description 3
- 241001453380 Burkholderia Species 0.000 claims description 3
- 241000588921 Enterobacteriaceae Species 0.000 claims description 3
- 241000192128 Gammaproteobacteria Species 0.000 claims description 3
- 241000947836 Pseudomonadaceae Species 0.000 claims description 3
- 241000589516 Pseudomonas Species 0.000 claims description 3
- 241001633102 Rhizobiaceae Species 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 241001135756 Alphaproteobacteria Species 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- OXIKLRTYAYRAOE-CMDGGOBGSA-N (e)-3-(1-benzyl-3-pyridin-3-ylpyrazol-4-yl)prop-2-enoic acid Chemical compound N1=C(C=2C=NC=CC=2)C(/C=C/C(=O)O)=CN1CC1=CC=CC=C1 OXIKLRTYAYRAOE-CMDGGOBGSA-N 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 65
- 102000004169 proteins and genes Human genes 0.000 abstract description 42
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 54
- 102000004190 Enzymes Human genes 0.000 description 41
- 108090000790 Enzymes Proteins 0.000 description 41
- 239000000872 buffer Substances 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 239000000243 solution Substances 0.000 description 25
- 241000588724 Escherichia coli Species 0.000 description 23
- 239000007983 Tris buffer Substances 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 21
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 238000006460 hydrolysis reaction Methods 0.000 description 18
- 230000007062 hydrolysis Effects 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 11
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 11
- 241001135514 Paraburkholderia caryophylli Species 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 238000004448 titration Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 108010006519 Molecular Chaperones Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229940041514 candida albicans extract Drugs 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 239000012064 sodium phosphate buffer Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000012138 yeast extract Substances 0.000 description 9
- HRTOQFBQOFIFEE-UHFFFAOYSA-N 2-dehydropantolactone Chemical compound CC1(C)COC(=O)C1=O HRTOQFBQOFIFEE-UHFFFAOYSA-N 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- OTOIIPJYVQJATP-BYPYZUCNSA-N (R)-pantoic acid Chemical compound OCC(C)(C)[C@@H](O)C(O)=O OTOIIPJYVQJATP-BYPYZUCNSA-N 0.000 description 7
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000001888 Peptone Substances 0.000 description 6
- 108010080698 Peptones Proteins 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 150000002596 lactones Chemical class 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 235000019319 peptone Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 5
- 108010058432 Chaperonin 60 Proteins 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 102000005431 Molecular Chaperones Human genes 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000000287 crude extract Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- -1 rp28 Proteins 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- PKVVTUWHANFMQC-UHFFFAOYSA-N 2-dehydropantoic acid Chemical compound OCC(C)(C)C(=O)C(O)=O PKVVTUWHANFMQC-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 4
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 241000187747 Streptomyces Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 230000007073 chemical hydrolysis Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N methyl tert-butyl ether Substances COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012289 standard assay Methods 0.000 description 3
- 239000012137 tryptone Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
- JJMOMMLADQPZNY-UHFFFAOYSA-N 3-hydroxy-2,2-dimethylpropanal Chemical compound OCC(C)(C)C=O JJMOMMLADQPZNY-UHFFFAOYSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000223679 Beauveria Species 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 2
- 108010059013 Chaperonin 10 Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 101710095468 Cyclase Proteins 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 2
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 2
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 2
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108030005682 Isatin hydrolases Proteins 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 241001237914 Psilocybe Species 0.000 description 2
- 239000012614 Q-Sepharose Substances 0.000 description 2
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 2
- 239000012722 SDS sample buffer Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 241000222050 Vanrija humicola Species 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000011138 biotechnological process Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011362 coarse particle Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000001400 expression cloning Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 229940099607 manganese chloride Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- ZNXZGRMVNNHPCA-UHFFFAOYSA-N pantetheine Chemical compound OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-UHFFFAOYSA-N 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 235000020957 pantothenol Nutrition 0.000 description 2
- 239000011619 pantothenol Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- CXNVOWPRHWWCQR-UHFFFAOYSA-N 4-Chloro-ortho-toluidine Chemical compound CC1=CC(Cl)=CC=C1N CXNVOWPRHWWCQR-UHFFFAOYSA-N 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001504907 Apiotrichum Species 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 1
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 1
- 241001523968 Beauveria amorpha Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000186146 Brevibacterium Species 0.000 description 1
- 241000589539 Brevundimonas diminuta Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000221778 Fusarium fujikuroi Species 0.000 description 1
- 241000146391 Fusarium lichenicola Species 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100023737 GrpE protein homolog 1, mitochondrial Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 1
- 101710100504 Heat shock protein beta-1 Proteins 0.000 description 1
- 102100023043 Heat shock protein beta-8 Human genes 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 101000829489 Homo sapiens GrpE protein homolog 1, mitochondrial Proteins 0.000 description 1
- 101001047341 Homo sapiens Heat shock protein beta-8 Proteins 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 241000108056 Monas Species 0.000 description 1
- 101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 241000350481 Pterogyne nitens Species 0.000 description 1
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
- 102100030262 Regucalcin Human genes 0.000 description 1
- 108050007056 Regucalcin Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100434411 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ADH1 gene Proteins 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000228389 Sporidiobolus Species 0.000 description 1
- 101000693619 Starmerella bombicola Lactone esterase Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000222665 Sterigmatomyces Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 102000006853 Strictosidine synthase Human genes 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 241000588902 Zymomonas mobilis Species 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 101150102866 adc1 gene Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 1
- 101150036359 clpB gene Proteins 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical group SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000007273 lactonization reaction Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- VGKONPUVOVVNSU-UHFFFAOYSA-N naphthalen-1-yl acetate Chemical compound C1=CC=C2C(OC(=O)C)=CC=CC2=C1 VGKONPUVOVVNSU-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000005484 prostate carcinoma in situ Diseases 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 108020005090 strictosidine synthase Proteins 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003774 sulfhydryl reagent Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/04—Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction
Definitions
- the present invention relates to proteins which have an enzymatic activity for the hydrolysis of L-pantolactone.
- the invention further relates to nucleic acids that code for these proteins, nucleic acid constructs, vectors, genetically modified microorganisms and a method for producing D-pantolactone.
- D-pantolactone is a precursor in the chemical synthesis or biosynthesis of pantothenic acid, panthenol and pantethein and their derivatives. These are used as vitamin additives in human nutrition, in animal feed, in medicine, for example for wound healing, and in cosmetics, for example in hair cosmetics. Economic processes for the synthesis of enantiomerically pure D-pantolactone are therefore of great importance
- pantolactone In addition to the long-established chemical processes for the production of D-pantolactone, various biotechnological processes have also recently been worked on. An overview of pantolactone and its chemical synthesis can be found in Ullmann's Encyclopedia of Industrial Chemistry (Vol. A27, 1996, VCH Verlagsgesellschaft mbH, 69451 Weinheim, pages 559-566).
- pantolactone Various synthetic strategies were pursued for the biotechnological synthesis of pantolactone.
- Degussa describes the production of pantolactone with the enzyme oxinitrilase starting from hydroxypivalaldehyde and hydrocyanic acid via optically pure hydroxypivalaldehyde cyanohydrin (DE 41 26 580, EP-A-0 528 256, DE 41 39 987). Theoretically, 100% yield can be achieved in this reaction. The disadvantage of this reaction is the high enzyme requirement (equimolar amounts Enzyme: substrate) and the relatively low enantiomeric purity of the product (max. 82% ee).
- JP 47019745 describes the synthesis of D-pantolactone using Arthrobacter, Brevibacterium, Bacillus or Corynebacterium.
- the organisms mentioned convert racemic pantolactone to D-pantolactone by metabolizing the L-pantolactone.
- the disadvantage of this process is that half of the starting material is metabolized and is therefore lost.
- ketopantolactone and ketopantoate oxidoreductases have also been described for bacteria (e.g. Yamada & Shimizu, see above; Shimizu et al., 1988, J. Biol. Chem. 263, 12077-12084, Kataoka et al. 1992, Eur. J Biochem. 204, 799-806).
- the Fuji company in cooperation with the Yamada working group at Kyoto University has developed a process for the enzymatic resolution using a fungal D-pantolactone hydrolase (JP 09308-497, JP 11056356, EP-B-0 436 730, EP- B-0 504 421, 5 EP-A-0 794 251, WO 92/06182, WO 97/10341, US 5,275,949,
- D-pantolactone hydrolase is a glycosylated enzyme that consists of a 125 kDa homodimer and
- nucleic acid sequences which, as a result of the degenerate genetic code, are derived from the nucleic acid sequence shown in SEQ ID NO: 1,
- L-pantolactone hydrolases can advantageously be found in organisms, microorganisms such as bacteria.
- the enzyme or the enzymes have a high enzymatic activity for the hydrolytic conversion of L-pantolactone into L-pantoic acid.
- L-pantolactone hydrolases do not convert D-pantolactone, so that the organisms, extracts or purified enzymes as well as corresponding recombinant strains or proteins can be used to produce enantiomerically pure D-pantolactone.
- Derivatives of the nucleic acid sequence according to the invention with the sequence SEQ ID NO: 1 are to be understood, for example, as allele variants which have at least 50% homology at the derived amino acid level, preferably at least 60% homology, particularly preferably 70%, very particularly preferably at least 80% homology. Homology was determined using either the method of Needleman & Wunsch (J. Mol. Biol. 48, 1970: 443-453) or Smith S Waterman (Adv. Appl. Math., 2, 1981: 482-489). The homologies can advantageously be higher over partial regions of the sequences.
- the amino acid sequence derived from SEQ ID NO: 1 can be found in SEQ ID NO: 2.
- Allelic variants include in particular functional variants which can be obtained by deleting, inserting or substituting nucleotides from the sequence shown in SEQ ID NO: 1, the enzymatic Activity of the derived synthesized proteins should not be significantly reduced. Enzymes with a not significantly reduced enzymatic activity are to be understood as enzymes which have an enzymatic activity of at least 20%, preferably 50%, particularly preferably 75%, very particularly preferably 90%.
- the invention thus also relates to amino acid sequences which are encoded by the group of nucleic acid sequences shown above.
- the invention advantageously relates to amino acid sequences which are encoded by the sequence SEQ ID NO: 1.
- Functional equivalents of the sequences mentioned under (a) to (c) are to be understood as nucleic acids which code for enzymes which hydrolyze L-pantolactone to the corresponding acid and which are at least 20%, preferably 50%, particularly preferably 75%, very particularly preferably Have 90% of the activity of the sequence mentioned under SEQ ID NO: 2, are not inhibited by EDTA (1 r ⁇ M solution) and are stable between pH 4 to 10.
- These functional equivalents also advantageously have a pH optimum between pH 7 and 8 and a temperature optimum between 70 ° C and 80 ° C.
- derivatives are also to be understood as homologs of SEQ ID NO: 1, for example fungal or bacterial homologs, shortened sequences, single-stranded DNA or RNA of the coding and non-coding DNA sequence.
- Homologs of SEQ ID NO: 1 have a homology at the DNA level of at least 50%, preferably at least 60%, particularly preferably at least 70%, very particularly preferably at least 80% over the entire DNA specified in SEQ ID NO: 1 -Area.
- homologs of SEQ ID NO: 1 are to be understood as derivatives such as promoter variants.
- the promoters which precede the specified nucleotide sequences can be changed by one or more nucleotide exchanges, by insertion (s) and / or deletion (s), but without the functionality or effectiveness of the promoters being impaired.
- the effectiveness of the promoters can be increased by changing their sequence, or completely replaced by more effective promoters, including organisms of other species.
- nucleic acid sequences according to the invention can be identified and isolated from all organisms.
- SEQ ID NO: 1 or its homologues can advantageously be isolated from fungi, yeasts or bacteria. Gram-negative and gram-positive bacteria are mentioned as bacteria.
- the nucleic acid (s) according to the invention are preferred from gram-negative bacteria, advantageously from ⁇ -proteobacteria, ⁇ -proteobacteria or ⁇ -proteobacteria, particularly preferably from bacteria of the Enterobacteriaceae, Pseudomonadaceae or Rhizobiaceae families , very particularly preferably isolated from bacteria of the genus Agrobacterium, Pseudomonas or Burkholderia using methods known to the person skilled in the art.
- the genera Beauveria or Psilocybe may be mentioned as advantageously suitable mushrooms.
- Advantageous yeasts can be found, for example, in the Apiotrichum genus.
- SEQ ID No: 1 or its derivatives, homologs or parts of these sequences can be isolated from other fungi or bacteria, for example, using conventional hybridization methods or the PCR technique.
- These DNA sequences hybridize under standard conditions with the sequences according to the invention.
- longer fragments of the nucleic acids according to the invention or the complete sequences can also be used for the hybridization.
- DNA hybrids are advantageously 2.0 ⁇ SSC and temperatures between approximately 20 ° C. to 70 ° C., preferably between approximately 50 ° C. to 70 ° C.
- DNA: RNA hybrids the hybridization conditions are advantageously 2.0 ⁇ SSC and temperatures between approximately 20 ° C. to 60 ° C., preferably between approximately 35 ° C. to 60 ° C.
- nucleic acid construct according to the invention are the nucleic acid construct according to the invention.
- L-pantolactone hydrolase genes with sequence SEQ ID No: 1 and its derivatives and homologues which were advantageously functionally linked to one or more regulatory signals to increase gene expression.
- these regulatory sequences are sequences to which inducers or repressors bind and thus regulate the expression of the nucleic acid.
- the natural regulation of these sequences may still be present before the actual structural genes and may have been genetically modified so that the natural regulation has been switched off and the expression of the genes increased.
- the nucleic acid construct can also have a simpler structure, that is to say no additional regulation signals have been inserted before the sequence SEQ ID No: 1 or its homologues and the natural promoter with its regulation has not been removed.
- the nucleic acid construct can also advantageously contain one or more so-called “enhancer sequences” functionally linked to the promoter, which enable increased expression of the nucleic acid sequence. Additional advantageous sequences, such as further regulatory elements or terminators, can also be inserted at the 3 'end of the DNA sequences.
- the nucleic acids according to the invention can be contained in the construct in one or more copies.
- the marker may also contain further markers such as antibiotic resistance or auxotrophy-complementing genes, optionally for selection on the construct.
- Advantageous regulatory sequences for the method according to the invention are, for example, in promoters such as aphll (Tn5) -, tre-, cos-, tac-, trp-, lacPAI, rha, tet-, trp-tet-, lpp-, lac-, lpp- lac-, lacl ⁇ 3-, T7-, T5-, T3-, gal-, trc-, ara-, SP6-, ⁇ -P R - or ⁇ -Pi, -promotor contain, which are advantageously in gram-negative bacteria Find application. Further advantageous regulatory sequences are found, for example, in the gram-positive promoters such as in the constitutive or inducible Streptomyces
- the promoters of pyruvate decarboxylase and methanol oxidase from, for example, Hansenula are also advantageous. Artificial promoters for regulation can also be used.
- the nucleic acid construct is advantageously inserted into a vector such as, for example, a plasmid, a phage or other DNA, which enables optimal expression of the genes in the host.
- a vector such as, for example, a plasmid, a phage or other DNA, which enables optimal expression of the genes in the host.
- plasmids mentioned represent a small selection of the possible plasmids. Further plasmids are well known to the person skilled in the art and can be found, for example, in the book Cloning Vectors (Eds. Pouwels PH et al. Elsevier, Amsterdam-New York-Oxford, 1985, ISBN 0 444 904018 ) can be removed.
- the nucleic acid construct for the expression of the further genes contained additionally contains 3 'and / or 5' terminal regulatory sequences for increasing expression, which are selected for optimal expression depending on the host organism selected and gene or genes.
- regulatory sequences are intended to enable targeted expression of the genes and protein expression. Depending on the host organism, this can mean, for example, that the gene is only expressed or overexpressed after induction, or that it is expressed and / or overexpressed immediately.
- the regulatory sequences or factors can preferably influence the gene expression of the introduced genes positively and thereby increase.
- the regulatory elements can advantageously be strengthened at the transcription level by using strong transcription signals such as promoters and / or "enhancers".
- an increase in translation is also possible, for example, by improving the stability of the mRNA.
- the vector containing the nucleic acid construct according to the invention or the nucleic acid according to the invention can also advantageously be introduced into the microorganisms in the form of a linear DNA and integrated into the genome of the host organism via heterologous or homologous recombination.
- This linear DNA can consist of a linearized vector such as a plasmid or only of the nucleic acid construct or the nucleic acid according to the invention.
- Another object of the invention is an L-pantolactone hydrolase, characterized by the following properties:
- L-pantolactone hydrolase is stable in a pH range from 4 to 10
- This L-pantolactone hydrolase can be used as a free or immobilized enzyme in the process according to the invention.
- the expression of the genes according to the invention and of the proteins encoded by these genes in a host organism generally involves stress for these organisms.
- the nucleic acids according to the invention can advantageously be expressed in the host organisms according to the invention.
- Gouvernante are among the best preserved proteins in evolution in both pro- and eukaryotes and can be found universally in all organisms. They are divided according to the molecular weight in kilodaltons, e.g. HSP60, 70, 10 90 etc. These stress proteins owe their name to their ability to be induced by stress conditions such as low glucose levels, heat shock, alcohol, UV light, oxidative reagents etc.
- a possible protein aggregation of the hydrolases can thus advantageously be prevented.
- the stress proteins bind to hydrophobic parts of the proteins and thus prevent incorrect folding of the proteins or enable correct folding.
- helper proteins cohort proteins
- HSP17 35 the eukaryotic genes HSP17, 5, HSP22, HSP 25, HSP27, HSP60, HSP70, HSP90, TRiC, UBI1,2,3,4 or their prokaryotic homologues such as HtpG, DnaK, DnaJ, GroES, GroEL, HtrC, ClpB, GrpE etc.
- Preferred chaperones are GroES, GroEL, HtpG, DnaK, DnaJ, HSP70 or H ⁇ P27.
- nucleic acids according to the invention are advantageously expressed in the presence of at least one stress protein; the genes can be under the joint control of a promoter or can be read by separate promoters. Accordingly, their
- Expression can be induced by adding one or more inductor substances simultaneously or at separate times.
- the nucleic acids can be on one vector or on separate ones Vectors. It is also possible to modify the host organism's stress proteins by genetic manipulation in such a way that they are overexpressed.
- prokaryotic or eukaryotic organisms are suitable as recombinant host organisms for the nucleic acid according to the invention or the nucleic acid construct.
- Microorganisms such as bacteria, fungi or yeasts are advantageously used as host organisms.
- Gram-positive or gram-negative bacteria are advantageous, preferably bacteria from the Enterobacteriaceae, Pseudomonadaceae, Rhizobiaceae, Streptomycetaeeae or Noeardiaeeae families, yeasts such as Piehia, Saccharomyces or Hansenula or fungi such as Beauveria or Psilocybe, particularly preferably bacteria of the genus Escherichia monas, Streptomyces, Nocardia, Burkholderia, Salmonella, Agrobacterium or Rhodococcus are used.
- the genus and type Escherichia coli is very particularly preferred.
- Further advantageous bacteria can also be found in the group of oc-proteobacteria, ß-proteobacteria or ⁇ -proteobacteria.
- nucleic acid sequences preferably contain at least one of the nucleic acid sequences, nucleic acid constructs or vectors described in this invention, which code for L-pantolactone hydrolases.
- Microorganisms are usually in a • liquid medium, which is a carbon source mostly in the form of sugars, a nitrogen source mostly in the form of organic
- Q Contains nitrogen sources such as yeast extract or salts such as ammonium sulfate, trace elements such as iron, manganese, magnesium salts and optionally vitamins at temperatures between 0 ° C and 100 ° C, preferably between 10 ° C and 60 ° C with gassing with oxygen.
- the pH of the nutrient liquid can be fixed
- the cultivation can be batch-wise, semi-batch wise or continuous. Nutrients can start at Bfeeg Fermentation submitted or fed semi-continuously or continuously. The same applies to inducers such as isopropythiogalactoside, (IPTG), lactose, arabinose, rhamnose and antibiotics or temperature shifts, which switch on the expression of the gene according to the invention, depending on the promoter used.
- inducers such as isopropythiogalactoside, (IPTG), lactose, arabinose, rhamnose and antibiotics or temperature shifts, which switch on the expression of the gene according to the invention, depending on the promoter used.
- IPTG isopropythiogalactoside
- lactose lactose
- arabinose arabinose
- rhamnose rhamnose
- antibiotics or temperature shifts
- the process according to the invention is advantageously carried out at a temperature between 0 ° C. to 95 ° C., preferably between 10 ° C. to 85 ° C., particularly preferably between 15 ° C. to 75 ° C.
- the pH in the process of the invention is advantageously kept between pH 4 and 12, preferably between pH 6 and 9, particularly preferably between pH 6 and 8, very particularly preferably between pH 6, 5 and 1 7 is held; 5.
- Racemic pantolactone in the process according to the invention is understood to mean pantolactone which consists of a 50:50 mixture of the two enantiomers or of any other mixture with an enrichment of one of the two enantiomers in the mixture.
- enantiomerically pure or chiral pantolactone (D or L enantiomer) is to be understood as enantiomers which show an enantiomer enrichment.
- Growing cells containing the nucleic acids, nucleic acid constructs or vectors according to the invention can be used for the method according to the invention.
- Dormant or disrupted cells can also be used.
- Disrupted cells are understood to mean, for example, cells which have been made permeable by treatment with, for example, solvents, or cells which have been broken up by means of enzyme treatment, by mechanical treatment (for example French press or ultrasound) or by some other method.
- the crude extracts obtained in this way are advantageous for the process according to the invention. suitable.
- Purified or purified enzymes can also be used for the process. Immobilized microorganisms or enzymes, which can advantageously be used in the reaction, are also suitable.
- the D-pantolactone produced in the process according to the invention can advantageously be obtained from the aqueous reaction solution by extraction or crystallization or advantageously by extraction and crystallization.
- the aqueous reaction solution is extracted with an organic solvent. The extraction can be repeated several times to increase the yield.
- the solution is advantageously cooled to about 0 ° C. to 10 ° C. before extraction.
- the aqueous solution is advantageously neutralized to about pH 6.0 to pH 7.0 in order to convert the free acid into the salt, so that it cannot be extracted under the reaction conditions.
- bicarbonate or another base such as NaOH or KOH is used.
- solvents can be used as organic solvents which show a phase boundary with water, if appropriate after addition of salts, and into which the lactone can pass from the aqueous phase.
- Advantageous solvents are solvents which absorb only a little water, so that only a little acid passes into the solvent, such as toluene, methylene chloride, butyl acetate, diisopropyl ether, benzene, methyl tert-butyl ether, methyl isobutyl ketone, diethyl ketone or ethyl acetate.
- the products can usually be obtained in good chemical purities, i.e. greater than 90% chemical purity.
- the organic phase with the product can also be only partially concentrated and the product crystallized out.
- the solution is advantageously cooled to a temperature of 0 ° C to 10 ° C. Crystallization can also take place directly from the organic solution or from an aqueous solution.
- the product which has crystallized out can be taken up again in the same or in a different solvent for recrystallization and can be crystallized again.
- the subsequent advantageous crystallization at least once can further increase the enantiomeric purity of the product if necessary.
- the resulting D-pantolactone can advantageously be used directly as an organic solution without crystallization.
- the L-enantiomer remaining in aqueous solution can be closed to form the lactone by acidic acids, for example with sulfuric acid, and then extracted as described above.
- the solution is advantageously heated for lactonization.
- the L-lactone obtained can be racemized and recycled with catalytic amounts (about 1 to 5% mol%) of a base such as NaOH, Na pantoate or Na methylate. Due to the advantageous racemization and recycling of the undesired enantiomer, a theoretical yield of 98% can be achieved in the process according to the invention.
- the product of the process according to the invention can be isolated in yields of from 60 to 100%, preferably from 80 to 100%, particularly preferably from 90 to 100%, based on the racemic pantolactone used for the reaction.
- the isolated product is characterized by a high chemical purity of> 90%, preferably> 95%, particularly preferably> 98%.
- the products have a high enantiomeric purity, which can advantageously be further increased by crystallization if necessary.
- the process according to the invention can be operated batchwise, semi-batchwise or continuously.
- panthenol, pantethein and their derivatives are suitable as starting materials for the synthesis of panthenol, pantethein and their derivatives.
- These substances and the enantiomerically pure pantolactone obtained can be used in combination with one another or alone for the production of pharmaceuticals, foods, animal feed or cosmetics.
- ketopantolactone, ketopantoic acid, D, L-pantolactone, D, L-, D- and L-pantoic acid were determined by HPLC analysis (Tab. La). All strains listed except Beauveria amorpha Lu7953 were able to reduce the ketopantoic acid formed from ketopantolactone by spontaneous hydrolysis to pantoic acid. However, since D-pantoic acid was formed in all strains instead of the L-pantoic acid described in Example 1, the conversion of pantolactone to L-pantoic acid cannot result from an oxidation reduction process (via ketopantolactone and ketopantoic acid).
- GYP 1% D-glucose, 0.5% polypeptone, 0.5% yeast extract
- HFP 1% peptone, 1% trypton, 0.5% yeast extract, 0.3% NaCl
- HFP 1% peptone, 1% trypton, 0.5% yeast extract, 0.3% NaCl
- the cells 1128 g wet weight
- an Ultra-Turrax rod 1.8 1, 20 mM Tris / HCl, pH 7.4
- Final volume 3 This solution was then freed from coarse particles on a glass suction filter through a bed of glass balls (0.1 to 0.2 mm, 200 ml).
- This cell suspension (3.2 l) was homogenized twice at 1500 bar in a Z04 microfluidizer.
- the device was rinsed with 500 ml of buffer.
- the combined volumes (4 l) were subjected to a first precipitation with 200 ml of an IM manganese chloride solution (final concentration 50 mM).
- the pH was kept at pH 7.0 by adding sodium hydroxide solution.
- the precipitate was centrifuged off at 6000 rpm for 30 minutes.
- 200 ml of a 0.2 M EDTA solution (pH 7.5) were added to the supernatant (3.1 l). With the addition, the pH dropped to 5.0.
- a precipitate formed which was again centrifuged off at 6000 rpm (20 minutes, Sorvall).
- the supernatant (3.4 l) was titrated back to pH 7.0.
- the phenyl-Sepharose column (Pharmacia, diameter 5 cm, height 25 cm, volume 490 ml) was washed with 1 1 buffer A (20 M sodium phosphate buffer, pH 7.4, 40% ammonium sulfate) and in the gradient with buffer B ( 20 mM sodium phosphate buffer, pH 7.4). At a flow of 10 ml / min, 100% buffer B was reached after 120 minutes and held for 40 minutes. Active fractions were collected and pooled (250 ml).
- TBS buffer 50 mM Tris, 100 mM NaCl, pH 7.4
- 50 ml TBS + 50 ml ⁇ -naphthylacetate solution Sigma N-8505, 0.4 g / 1 in 10% acetone
- the cells (400 g wet mass) of Agrobacterium radiobacter (Lu 5351) were first resuspended by treatment with an Ultra-Turrax rod in the buffer (1.8 1, 20 mM Tris / HCl, pH 7.4) (final volume 2, 2 1).
- This solution was then freed from coarse particles on a glass suction filter through a bed of glass balls (0.1 to 0.2 mm, 200 ml).
- This cell suspension was homogenized twice at 1500 bar in the Z04 microfluidizer.
- the device was rinsed with 500 ml of buffer.
- the combined volumes (2.7 l) were subjected to a first precipitation with 135 ml of a 1 M manganese chloride solution (final concentration 50 mM).
- the pH was kept at pH 7.0 by adding sodium hydroxide solution and the precipitate was centrifuged off at 6000 rpm for 30 min.
- the supernatant (2.6 l) was mixed with 575 ml of a 0.2 M EDTA solution and the pH checked again.
- the phenyl-Sepharose column (Pharmacia, diameter 5 cm, height 25 cm, volume 490 ml) was washed with 1 1 buffer A (20 mM sodium phosphate buffer, pH 7.4, 40% ammonium sulfate) and in the gradient with buffer B ( 20 mM sodium phosphate buffer, pH 7.4). At a flow of 10 ml / min, 100% B was reached after 120 min and held for 40 min. Active fractions were collected and pooled (350 ml, 20.9 mS).
- the Mono-P fractions were concentrated in 0.2 ml portions by acetone precipitation at -20 degrees Celsius.
- the pellets were then taken up in 0.005 ml SDS sample buffer without DTT and placed on an SDS gel.
- the L-pantolactone hydrolase was identified by an activity staining (see Example 4) and cut out. It was recognizable as a red-brown colored band with an apparent molecular weight of 36 kDa.
- the protein in the cut gel pieces was digested by trypsin and the peptides were sequenced. The remaining gel was stained with Coomassie Blue. Two peptide sequences (SEQ ID NO: 5 and 6) were obtained. Sequencing of SEQ ID NO: 5 revealed ambiguity for the first amino acid in the sequence. The tyrosine shown in position 1 can also be a leucine, the sequence was not clear here. 6.
- Lu5351 insensitive (> 85% residual activity) to chelating substances, SH reagents, protease inhibitors, detergents (exception: Lu5351 with 74% residual activity in 1% SDS) and various cations.
- Genbank + screening cloning of L-pantolactone hydrolase from Burkholderia caryophylli Lu681
- Genomic DNA from Burkholderia caryophylli Lu681 was isolated (Qiagen, Hilden), digested with EcoRI and ligated into pBluescriptKS + vector cut and dephosphorylated with EcoRI (Maniatis, T., Molecular Cloning: A laboratory manual, 1989).
- the ligation mixture was transformed into E. coli XLlBlue according to the instructions from Stratagene (La Jolla, Calif.). The
- the plasmid DNA was isolated from E. coli XLlBlue pKS + 681 in accordance with the instructions from Qiagen (Hilden) and cut individually or in a double digest with the restriction enzymes EcoRI, BamHI, PstI and HindIII. The fragmented DNA was cut through
- SEQ ID NO: 2 in turn contains the peptides YGIEGLNNLEAL and AKEDANSTIEAED (SEQ ID NO: 3 and 4), which were found after tryptic digestion of the purified and blotted L-pantolactone hydrolase from Burkholderia caryophylli Lu681 and Agrobacterium radiobacter Lu5351 (see Examples 4 and 5).
- GACCAGGGCCAGAA (P2) derived as a primer for a PCR amplification of the L-pantolactone hydrolase gene under the following conditions: 20 mM Tris / HCl pH 8, 8, 2 mM MgSO 4 , 10 mM KC1, 10 mM ( NH 4 ) 2 S0 4 , 0.1% Triton X-100, 0.1 mg / ml BSA, 25 mM per dNTP, 0.96 ⁇ g / ml pKS + 681, 2.2 ⁇ g / ml Pl and P2, 25U / ml Pfu polymerase
- E. coli XLlBlue pKK681 was grown in 30 ml LB medium with ampicillin (100 ⁇ g / ml) and IPTG (0.5 mM) overnight at 37 ° C., harvested and in Tris-HCl buffer (50 mM, pH 7 , 0) washed 0 and resuspended (3 ml 50 mM Tris / HCl pH 7.0). 0.25 ml of
- Suspension was treated with 150 mM L-pantolactone, 150 mM pipes pH 7, 0 ad 0.5 ml A. dest. added and incubated at 30 ° C for 3 h.
- 35 GACCAGGGCCAGAA (P2) derived as a primer for a PCR amplification of the L-pantolactone hydrolase gene under the following conditions: 20 mM Tris-HCl pH 8, 8, 2 mM MgSO, 10 mM KC1, 10 mM (NH 4 ) 2 S0, 0.1% Triton X-100, 0.1 mg / ml BSA, 25 mM per dNTP, 0.96 ⁇ g / ml pKS + 681, 2.2 ⁇ g / ml Pl and P2, 25U / ml Pfu polymerase
- PCR 40 (Stratagene, LaJolla, Calif.); The PCR parameters were as follows: 1 min 95 ° C, 1 min 55 ° C, 2.5 min 72 ° C, 30 cycles.
- the PCR product obtained (0.8 kB) was cut with Ndel and Hindlll and ligated into pDHEl9 (Prof. Mattes, Stuttgart) cut and dephosphorylated with Ndel and Hindlll.
- E. coli XLl Blue or TG1 (Stratagene, LaJolla, Calif .; DSMZ, Braunschweig, DSMZ No. 6056, Inoue et al, 1990, Gene 96: 23-28).
- E. coli TG1 pDHE681 was grown in 14 l minimal medium with 40 g / l glycine and 2.5 g / l rhamnose for 6 to 7 h at 37 ° C., harvested and washed with Tris / HCl buffer (50 mM, pH 7.0) and ad 1.4 1 buffer resuspended.
- the activity of the single-concentrated cell suspension in the standard assay 150 mM pipes pH 7.0, 150 mM L-pantolactone, 1 h 30 ° C. was 680 to 2700 U / 1 or 60 to 160 g / BTM.
- the aqueous phase (21 ml; Na-L-Pantoat) was adjusted to pH 1 with about 5 ml of 3 MH 2 S0 4 , heated at 80 ° C. for 15 minutes and mixed with 8 g of anhydrous Na 2 S0 4 .
- the L-pantolactone obtained was extracted analogously 3 times with a volume of ethyl acetate, dried with Na 2 SO 4 and evaporated.
- the L-pantolactone melt can be racemized by heating after adding NaOH in the presence of small amounts of Na-L-pantoate (3 h at 180 ° C.).
- L-pantolactone hydrolase was obtained directly from fermentation broth from E. coli (TG1 pDHE681 or preferential strains which co-express chaperones such as GroEL) by cell disruption (2 x 1000 bar in a 0 microfluidizer), cell debris separation (20 min 9000 g at 10 ° C), 10-fold concentration via cross-flow filtration (Hämoflow F60, Fresenius, membrane with exclusion of approx. 10 kDa) and heat precipitation (20 min 60 ° C, 20 min RT-10 ° C, centrifugation) and a specific activity of about 3000 U / g protein
- This 10 x homogenate had an activity of 63-100000 U / 1 and a protein concentration of 20-30 g / 1.
- Racemate resolution batches were worked up with homogenate (50.8% conversion, 92.5% ee) by extraction with 5 x 1 45 vol. MTBE. 43% D-pantolactone with 91.4% ee and 98.2%
- L-pantolactone hydrolase was isolated as in Example 16 and bound to various carrier materials such as the commercially available EupergitC (Röhm GmbH, Darmstadt) or Deloxan DAPIII (Degussa, Frankfurt).
- Eupergit is a carrier material activated by epoxy groups. As a result, the protein is mainly covalently fixed to amino groups.
- Homogenate was first subjected to precipitation by heat treatment. 1.11 homogenate was incubated in amounts of 550 ml each for 30 minutes at 60 ° C. and then placed on ice for 20 minutes to cool. This solution was centrifuged (1 hour 8000 rpm GS3 rotor) to separate denatured protein. The supernatant was then concentrated on a Hemoflow F40 cartridge and re-buffered in a 20 mM HEPES buffer, pH 7.5. The amount of protein per g of Eupergite can be chosen freely.
- Deloxan is a silicate modified with amino groups. These amino groups can be activated with glutardialdehyde to form a Schiff base. The excess aldehyde is then washed away and the protein is added to the activated carrier. The free amino groups of the protein react with the formation of a second Schiff's base with the still free aldehyde of the bound glutardialdehyde. This protein immobilized in this way can already be used. However, the Schiff's base tends to hydrolize, so that the protein slowly bleeds from the carrier in aqueous solution. This can be avoided by reduction with sodium borohydride. The ship's base is converted into a secondary amine. The prerequisite for this is the stability of the enzyme against reduction with sodium borohydride.
- activated deloxane were Given 10,000 U (approx.2.7 g protein) L-pantolactone hydrolase.
- the protein was incubated with the activated carrier for 18 hours at room temperature.
- the solution was separated from the support via a glass suction filter.
- the support was washed several times with water and then with 1 1 0.1M phosphate buffer, pH 7, 2 and 1 M NaCl.
- Half of the carrier was removed (without reduction). The other half was washed again with water and then placed in 0.1 M sodium borate buffer, pH 7.2.
- Reduction with sodium borohydride :
- pantoic acid ee values refer to the formation of (L) -pantoic acid ee, enantiomeric excess, corrected, corrected ee after deduction of those formed by chemical hydrolysis
- ee values refer to the formation of (L) -pantoic acid
- pCMBS p-chloromercurbiphenylsulfonic acid
- SDS sodium dodecyl sulfate
- EDTA ethylenediaminetetraacetic acid
- DIFP diisopropyl fluorophosphate
- Table 5 Homologies of the L-pantolactone hydrolase amino acid sequence from Lu681 according to gap 4 or bestfit 5 search
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19952501A DE19952501A1 (en) | 1999-10-29 | 1999-10-29 | New nucleic acid encoding L-pantolactone hydrolase, useful for producing pure D-pantolactone, an intermediate for vitamins, from its racemate |
| DE19952501 | 1999-10-29 | ||
| DE10029194 | 2000-06-19 | ||
| DE10029194A DE10029194A1 (en) | 2000-06-19 | 2000-06-19 | New isolated nucleic acid encoding L-pantolactone hydrolase, useful for production of optically pure D-pantolactone from its racemate |
| PCT/EP2000/010320 WO2001032890A1 (en) | 1999-10-29 | 2000-10-20 | L-pantolactone-hydrolase and a method for producing d-pantolactone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1224296A1 true EP1224296A1 (en) | 2002-07-24 |
Family
ID=26006072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP00972817A Withdrawn EP1224296A1 (en) | 1999-10-29 | 2000-10-20 | L-pantolactone-hydrolase and a method for producing d-pantolactone |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6998258B1 (en) |
| EP (1) | EP1224296A1 (en) |
| JP (1) | JP2003530080A (en) |
| KR (1) | KR20020043254A (en) |
| CN (1) | CN1384880A (en) |
| AU (1) | AU782517B2 (en) |
| BR (1) | BR0015114A (en) |
| CA (1) | CA2389064A1 (en) |
| CZ (1) | CZ20021449A3 (en) |
| EE (1) | EE200200225A (en) |
| HU (1) | HUP0203704A3 (en) |
| IL (1) | IL148973A0 (en) |
| MX (1) | MXPA02003417A (en) |
| NO (1) | NO20021931L (en) |
| PL (1) | PL355487A1 (en) |
| RU (1) | RU2002114044A (en) |
| WO (1) | WO2001032890A1 (en) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030194798A1 (en) * | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| DK1570060T3 (en) | 2002-12-02 | 2007-11-05 | Basf Ag | L-rhamnose-inducible expression systems |
| CN1768141B (en) * | 2003-03-28 | 2012-10-10 | 帝斯曼知识产权资产管理有限公司 | Pantolactone hydrolase |
| DE112007001179T5 (en) * | 2006-05-16 | 2009-04-02 | Dsm Ip Assets B.V. | Process for the preparation of panthenol |
| AU2007277081B2 (en) * | 2006-07-27 | 2014-02-06 | Wyeth Llc | High-cell density fed-batch fermentation process for producing recombinant protein |
| US8598543B2 (en) * | 2008-05-22 | 2013-12-03 | Vladimir Balakin | Multi-axis/multi-field charged particle cancer therapy method and apparatus |
| US10143854B2 (en) | 2008-05-22 | 2018-12-04 | Susan L. Michaud | Dual rotation charged particle imaging / treatment apparatus and method of use thereof |
| US8373143B2 (en) * | 2008-05-22 | 2013-02-12 | Vladimir Balakin | Patient immobilization and repositioning method and apparatus used in conjunction with charged particle cancer therapy |
| US8718231B2 (en) | 2008-05-22 | 2014-05-06 | Vladimir Balakin | X-ray tomography method and apparatus used in conjunction with a charged particle cancer therapy system |
| US9177751B2 (en) | 2008-05-22 | 2015-11-03 | Vladimir Balakin | Carbon ion beam injector apparatus and method of use thereof |
| US9056199B2 (en) | 2008-05-22 | 2015-06-16 | Vladimir Balakin | Charged particle treatment, rapid patient positioning apparatus and method of use thereof |
| US8188688B2 (en) * | 2008-05-22 | 2012-05-29 | Vladimir Balakin | Magnetic field control method and apparatus used in conjunction with a charged particle cancer therapy system |
| US9155911B1 (en) | 2008-05-22 | 2015-10-13 | Vladimir Balakin | Ion source method and apparatus used in conjunction with a charged particle cancer therapy system |
| US10029122B2 (en) | 2008-05-22 | 2018-07-24 | Susan L. Michaud | Charged particle—patient motion control system apparatus and method of use thereof |
| US8569717B2 (en) * | 2008-05-22 | 2013-10-29 | Vladimir Balakin | Intensity modulated three-dimensional radiation scanning method and apparatus |
| US8309941B2 (en) * | 2008-05-22 | 2012-11-13 | Vladimir Balakin | Charged particle cancer therapy and patient breath monitoring method and apparatus |
| US9744380B2 (en) | 2008-05-22 | 2017-08-29 | Susan L. Michaud | Patient specific beam control assembly of a cancer therapy apparatus and method of use thereof |
| US10684380B2 (en) | 2008-05-22 | 2020-06-16 | W. Davis Lee | Multiple scintillation detector array imaging apparatus and method of use thereof |
| US8637833B2 (en) | 2008-05-22 | 2014-01-28 | Vladimir Balakin | Synchrotron power supply apparatus and method of use thereof |
| US8089054B2 (en) | 2008-05-22 | 2012-01-03 | Vladimir Balakin | Charged particle beam acceleration and extraction method and apparatus used in conjunction with a charged particle cancer therapy system |
| US9168392B1 (en) | 2008-05-22 | 2015-10-27 | Vladimir Balakin | Charged particle cancer therapy system X-ray apparatus and method of use thereof |
| US9974978B2 (en) | 2008-05-22 | 2018-05-22 | W. Davis Lee | Scintillation array apparatus and method of use thereof |
| US9782140B2 (en) | 2008-05-22 | 2017-10-10 | Susan L. Michaud | Hybrid charged particle / X-ray-imaging / treatment apparatus and method of use thereof |
| US8378311B2 (en) | 2008-05-22 | 2013-02-19 | Vladimir Balakin | Synchrotron power cycling apparatus and method of use thereof |
| US8129699B2 (en) | 2008-05-22 | 2012-03-06 | Vladimir Balakin | Multi-field charged particle cancer therapy method and apparatus coordinated with patient respiration |
| US8975600B2 (en) | 2008-05-22 | 2015-03-10 | Vladimir Balakin | Treatment delivery control system and method of operation thereof |
| US9616252B2 (en) | 2008-05-22 | 2017-04-11 | Vladimir Balakin | Multi-field cancer therapy apparatus and method of use thereof |
| US8969834B2 (en) | 2008-05-22 | 2015-03-03 | Vladimir Balakin | Charged particle therapy patient constraint apparatus and method of use thereof |
| US8178859B2 (en) | 2008-05-22 | 2012-05-15 | Vladimir Balakin | Proton beam positioning verification method and apparatus used in conjunction with a charged particle cancer therapy system |
| US9737272B2 (en) | 2008-05-22 | 2017-08-22 | W. Davis Lee | Charged particle cancer therapy beam state determination apparatus and method of use thereof |
| US8198607B2 (en) * | 2008-05-22 | 2012-06-12 | Vladimir Balakin | Tandem accelerator method and apparatus used in conjunction with a charged particle cancer therapy system |
| US9737734B2 (en) | 2008-05-22 | 2017-08-22 | Susan L. Michaud | Charged particle translation slide control apparatus and method of use thereof |
| US7939809B2 (en) * | 2008-05-22 | 2011-05-10 | Vladimir Balakin | Charged particle beam extraction method and apparatus used in conjunction with a charged particle cancer therapy system |
| US8378321B2 (en) * | 2008-05-22 | 2013-02-19 | Vladimir Balakin | Charged particle cancer therapy and patient positioning method and apparatus |
| US9682254B2 (en) | 2008-05-22 | 2017-06-20 | Vladimir Balakin | Cancer surface searing apparatus and method of use thereof |
| US8368038B2 (en) | 2008-05-22 | 2013-02-05 | Vladimir Balakin | Method and apparatus for intensity control of a charged particle beam extracted from a synchrotron |
| US8710462B2 (en) * | 2008-05-22 | 2014-04-29 | Vladimir Balakin | Charged particle cancer therapy beam path control method and apparatus |
| US8642978B2 (en) * | 2008-05-22 | 2014-02-04 | Vladimir Balakin | Charged particle cancer therapy dose distribution method and apparatus |
| US9910166B2 (en) | 2008-05-22 | 2018-03-06 | Stephen L. Spotts | Redundant charged particle state determination apparatus and method of use thereof |
| US9737733B2 (en) | 2008-05-22 | 2017-08-22 | W. Davis Lee | Charged particle state determination apparatus and method of use thereof |
| US8373145B2 (en) * | 2008-05-22 | 2013-02-12 | Vladimir Balakin | Charged particle cancer therapy system magnet control method and apparatus |
| US9579525B2 (en) | 2008-05-22 | 2017-02-28 | Vladimir Balakin | Multi-axis charged particle cancer therapy method and apparatus |
| US9044600B2 (en) * | 2008-05-22 | 2015-06-02 | Vladimir Balakin | Proton tomography apparatus and method of operation therefor |
| US10092776B2 (en) | 2008-05-22 | 2018-10-09 | Susan L. Michaud | Integrated translation/rotation charged particle imaging/treatment apparatus and method of use thereof |
| US20090314960A1 (en) * | 2008-05-22 | 2009-12-24 | Vladimir Balakin | Patient positioning method and apparatus used in conjunction with a charged particle cancer therapy system |
| US10548551B2 (en) | 2008-05-22 | 2020-02-04 | W. Davis Lee | Depth resolved scintillation detector array imaging apparatus and method of use thereof |
| US9095040B2 (en) | 2008-05-22 | 2015-07-28 | Vladimir Balakin | Charged particle beam acceleration and extraction method and apparatus used in conjunction with a charged particle cancer therapy system |
| US8373146B2 (en) * | 2008-05-22 | 2013-02-12 | Vladimir Balakin | RF accelerator method and apparatus used in conjunction with a charged particle cancer therapy system |
| US9937362B2 (en) | 2008-05-22 | 2018-04-10 | W. Davis Lee | Dynamic energy control of a charged particle imaging/treatment apparatus and method of use thereof |
| US10070831B2 (en) | 2008-05-22 | 2018-09-11 | James P. Bennett | Integrated cancer therapy—imaging apparatus and method of use thereof |
| US8288742B2 (en) * | 2008-05-22 | 2012-10-16 | Vladimir Balakin | Charged particle cancer therapy patient positioning method and apparatus |
| US8374314B2 (en) | 2008-05-22 | 2013-02-12 | Vladimir Balakin | Synchronized X-ray / breathing method and apparatus used in conjunction with a charged particle cancer therapy system |
| US8624528B2 (en) * | 2008-05-22 | 2014-01-07 | Vladimir Balakin | Method and apparatus coordinating synchrotron acceleration periods with patient respiration periods |
| US8907309B2 (en) | 2009-04-17 | 2014-12-09 | Stephen L. Spotts | Treatment delivery control system and method of operation thereof |
| US9981147B2 (en) | 2008-05-22 | 2018-05-29 | W. Davis Lee | Ion beam extraction apparatus and method of use thereof |
| US9855444B2 (en) | 2008-05-22 | 2018-01-02 | Scott Penfold | X-ray detector for proton transit detection apparatus and method of use thereof |
| US8399866B2 (en) | 2008-05-22 | 2013-03-19 | Vladimir Balakin | Charged particle extraction apparatus and method of use thereof |
| US8519365B2 (en) * | 2008-05-22 | 2013-08-27 | Vladimir Balakin | Charged particle cancer therapy imaging method and apparatus |
| US9498649B2 (en) | 2008-05-22 | 2016-11-22 | Vladimir Balakin | Charged particle cancer therapy patient constraint apparatus and method of use thereof |
| US8436327B2 (en) * | 2008-05-22 | 2013-05-07 | Vladimir Balakin | Multi-field charged particle cancer therapy method and apparatus |
| US8625739B2 (en) | 2008-07-14 | 2014-01-07 | Vladimir Balakin | Charged particle cancer therapy x-ray method and apparatus |
| US8627822B2 (en) * | 2008-07-14 | 2014-01-14 | Vladimir Balakin | Semi-vertical positioning method and apparatus used in conjunction with a charged particle cancer therapy system |
| US8229072B2 (en) * | 2008-07-14 | 2012-07-24 | Vladimir Balakin | Elongated lifetime X-ray method and apparatus used in conjunction with a charged particle cancer therapy system |
| ES2703770T3 (en) | 2009-06-05 | 2019-03-12 | Basf Se | Biocatalytic preparation of ambroxan |
| US10376717B2 (en) | 2010-04-16 | 2019-08-13 | James P. Bennett | Intervening object compensating automated radiation treatment plan development apparatus and method of use thereof |
| US10638988B2 (en) | 2010-04-16 | 2020-05-05 | Scott Penfold | Simultaneous/single patient position X-ray and proton imaging apparatus and method of use thereof |
| US10556126B2 (en) | 2010-04-16 | 2020-02-11 | Mark R. Amato | Automated radiation treatment plan development apparatus and method of use thereof |
| US10751551B2 (en) | 2010-04-16 | 2020-08-25 | James P. Bennett | Integrated imaging-cancer treatment apparatus and method of use thereof |
| US10188877B2 (en) | 2010-04-16 | 2019-01-29 | W. Davis Lee | Fiducial marker/cancer imaging and treatment apparatus and method of use thereof |
| US10179250B2 (en) | 2010-04-16 | 2019-01-15 | Nick Ruebel | Auto-updated and implemented radiation treatment plan apparatus and method of use thereof |
| US10518109B2 (en) | 2010-04-16 | 2019-12-31 | Jillian Reno | Transformable charged particle beam path cancer therapy apparatus and method of use thereof |
| US11648420B2 (en) | 2010-04-16 | 2023-05-16 | Vladimir Balakin | Imaging assisted integrated tomography—cancer treatment apparatus and method of use thereof |
| US10589128B2 (en) | 2010-04-16 | 2020-03-17 | Susan L. Michaud | Treatment beam path verification in a cancer therapy apparatus and method of use thereof |
| US10349906B2 (en) | 2010-04-16 | 2019-07-16 | James P. Bennett | Multiplexed proton tomography imaging apparatus and method of use thereof |
| US10086214B2 (en) | 2010-04-16 | 2018-10-02 | Vladimir Balakin | Integrated tomography—cancer treatment apparatus and method of use thereof |
| US9737731B2 (en) | 2010-04-16 | 2017-08-22 | Vladimir Balakin | Synchrotron energy control apparatus and method of use thereof |
| US10555710B2 (en) | 2010-04-16 | 2020-02-11 | James P. Bennett | Simultaneous multi-axes imaging apparatus and method of use thereof |
| US10625097B2 (en) | 2010-04-16 | 2020-04-21 | Jillian Reno | Semi-automated cancer therapy treatment apparatus and method of use thereof |
| US8963112B1 (en) | 2011-05-25 | 2015-02-24 | Vladimir Balakin | Charged particle cancer therapy patient positioning method and apparatus |
| US8933651B2 (en) | 2012-11-16 | 2015-01-13 | Vladimir Balakin | Charged particle accelerator magnet apparatus and method of use thereof |
| JP2018524317A (en) * | 2015-06-19 | 2018-08-30 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | Production of pantolactone |
| US9907981B2 (en) | 2016-03-07 | 2018-03-06 | Susan L. Michaud | Charged particle translation slide control apparatus and method of use thereof |
| US10037863B2 (en) | 2016-05-27 | 2018-07-31 | Mark R. Amato | Continuous ion beam kinetic energy dissipater apparatus and method of use thereof |
| US12203114B2 (en) | 2018-10-18 | 2025-01-21 | Basf Se | Method for the production of acrylic acid or salts thereof |
| EP3748009A1 (en) * | 2019-06-07 | 2020-12-09 | DSM IP Assets B.V. | Synthesis of (r)-pantolactone acetate |
| CN110452861B (en) * | 2019-07-10 | 2021-02-09 | 杭州师范大学 | A kind of genetic recombination engineering bacteria and its application in catalyzing synthesis of D-pantolactone |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5572182A (en) * | 1978-11-28 | 1980-05-30 | Sagami Chem Res Center | Optical resolution of pantolactone |
| JPH0667320B2 (en) * | 1986-06-13 | 1994-08-31 | 三菱化成株式会社 | Method for producing D-pantolactone |
| JPH0655156B2 (en) * | 1986-06-13 | 1994-07-27 | 三菱化成株式会社 | Optical resolution method of DL-pantolactone |
| JP2844354B2 (en) | 1989-08-03 | 1999-01-06 | 富士薬品工業株式会社 | Method for producing D-pantolactone |
| DE4005150A1 (en) | 1990-02-17 | 1991-08-22 | Hoechst Ag | METHOD FOR THE ENZYMATIC RACEMATE CLEAVAGE OF PANTOLACTON |
| JP3011449B2 (en) | 1990-10-05 | 2000-02-21 | 富士薬品工業株式会社 | D-pantolactone hydrolase and method for producing the same |
| EP0507278A3 (en) | 1991-04-02 | 1993-12-15 | Hoechst Ag | Immobilised biocatalyser, its preparation and use for ester synthesis in a column reactor |
| DE4126580A1 (en) | 1991-08-12 | 1993-02-18 | Degussa | D-2,4-DIHYDROXY-3,3-DIMETHYLBUTANESAEURENITRILE, ITS PRODUCTION AND USE |
| WO1994009175A1 (en) | 1992-10-15 | 1994-04-28 | Kawasaki Steel Corporation | Method of continuously carburizing metal strip |
| EP0794251B1 (en) * | 1995-09-13 | 2005-06-08 | Daiichi Fine Chemical Co., Ltd. | D-pantolactone hydrolase and gene encoding the same |
| JP2003512015A (en) | 1998-11-10 | 2003-04-02 | ノボザイムス バイオテック,インコーポレイティド | Polypeptide having lactohydrolase activity and nucleic acid encoding the same |
| US6395529B1 (en) * | 1998-11-10 | 2002-05-28 | Novozymes Biotech, Inc. | Polypeptides having lactonohydrolase activity and nucleic acids encoding same |
-
2000
- 2000-10-20 EP EP00972817A patent/EP1224296A1/en not_active Withdrawn
- 2000-10-20 PL PL00355487A patent/PL355487A1/en not_active Application Discontinuation
- 2000-10-20 BR BR0015114-9A patent/BR0015114A/en not_active IP Right Cessation
- 2000-10-20 HU HU0203704A patent/HUP0203704A3/en unknown
- 2000-10-20 EE EEP200200225A patent/EE200200225A/en unknown
- 2000-10-20 CN CN00814937A patent/CN1384880A/en active Pending
- 2000-10-20 IL IL14897300A patent/IL148973A0/en unknown
- 2000-10-20 JP JP2001535572A patent/JP2003530080A/en not_active Withdrawn
- 2000-10-20 US US10/111,451 patent/US6998258B1/en not_active Expired - Fee Related
- 2000-10-20 RU RU2002114044/13A patent/RU2002114044A/en not_active Application Discontinuation
- 2000-10-20 CA CA002389064A patent/CA2389064A1/en not_active Abandoned
- 2000-10-20 CZ CZ20021449A patent/CZ20021449A3/en unknown
- 2000-10-20 MX MXPA02003417A patent/MXPA02003417A/en unknown
- 2000-10-20 AU AU11416/01A patent/AU782517B2/en not_active Ceased
- 2000-10-20 KR KR1020027005466A patent/KR20020043254A/en not_active Withdrawn
- 2000-10-20 WO PCT/EP2000/010320 patent/WO2001032890A1/en not_active Ceased
-
2002
- 2002-04-24 NO NO20021931A patent/NO20021931L/en not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0132890A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA02003417A (en) | 2002-08-20 |
| RU2002114044A (en) | 2004-03-27 |
| AU1141601A (en) | 2001-05-14 |
| IL148973A0 (en) | 2002-11-10 |
| EE200200225A (en) | 2003-06-16 |
| CA2389064A1 (en) | 2001-05-10 |
| PL355487A1 (en) | 2004-05-04 |
| CN1384880A (en) | 2002-12-11 |
| NO20021931D0 (en) | 2002-04-24 |
| JP2003530080A (en) | 2003-10-14 |
| WO2001032890A1 (en) | 2001-05-10 |
| AU782517B2 (en) | 2005-08-04 |
| BR0015114A (en) | 2002-07-16 |
| HUP0203704A3 (en) | 2006-03-28 |
| NO20021931L (en) | 2002-04-24 |
| HUP0203704A2 (en) | 2003-03-28 |
| US6998258B1 (en) | 2006-02-14 |
| CZ20021449A3 (en) | 2002-10-16 |
| KR20020043254A (en) | 2002-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1224296A1 (en) | L-pantolactone-hydrolase and a method for producing d-pantolactone | |
| EP1123386B1 (en) | Method for producing chiral carboxylic acids from nitriles with the assistance of a nitrilase or microorganisms which contain a gene for the nitrilase | |
| US5037751A (en) | Microbial purified esterases | |
| EP0909821B1 (en) | Engineering enzymes having altered substrate specificity | |
| CN101535467B (en) | A levorotatory lactonohydrolase producing strain and its use for producing chiral oxyacid | |
| EP3417067B1 (en) | Enzymatic cyclisation of homofarnesylic acid | |
| EP0299558A1 (en) | Process for the preparation of ibuprofen | |
| EP1613745B1 (en) | L-carnitin dehydrogenases, their derivatives and method for producing substituted (s) alkanols | |
| Li et al. | Production, characterization, and application of an organic solvent-tolerant lipase present in active inclusion bodies | |
| DE10010149A1 (en) | New nucleic acid encoding nitrilase, useful for converting aromatic nitriles to carboxylic acid, pharmaceutical intermediates, isolated from Rhodococcus rhodochrous | |
| DE102007014742A1 (en) | Isoforms of pork liver esterase | |
| DE10029194A1 (en) | New isolated nucleic acid encoding L-pantolactone hydrolase, useful for production of optically pure D-pantolactone from its racemate | |
| EP0299559B1 (en) | Process for the preparation of 2-aryloxypropionic acids | |
| DE19952501A1 (en) | New nucleic acid encoding L-pantolactone hydrolase, useful for producing pure D-pantolactone, an intermediate for vitamins, from its racemate | |
| WO2007071578A2 (en) | Method for producing 5-norbornen-2-carboxylic acid from 5-norbornen-2-carbonitrile using an arylacetonitrilase | |
| Bianchi et al. | Substrate specificity and stereoselectivity of hydrolytic enzymes from Brevibacterium imperiale B222 | |
| EP0648277B1 (en) | Microbial esterase for the enantioselective cleavage of 1-arylalkylesters | |
| EP0912751B1 (en) | Process for preparation of d-proline derivatives by means of micro-organisms | |
| JP3917723B2 (en) | Lactone hydrolase and process for producing the same | |
| JPH05227987A (en) | Production of d-pantolactone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20020406 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT PAYMENT 20020406;LV PAYMENT 20020406;MK;RO;SI PAYMENT 20020406 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MATTES, RALF Inventor name: FRIEDRICH, THOMAS Inventor name: HAUER, BERNHARD Inventor name: KESSELER, MARIA |
|
| 17Q | First examination report despatched |
Effective date: 20040803 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20060503 |